Can-Fite Pancreatic Cancer Data Shows Durable Response, Extended Treatment
Event summary
- Can-Fite BioPharma reported Phase 2a data for namodenoson in advanced pancreatic cancer.
- The study showed stable disease in over 30% of evaluable patients.
- A notable 35% of patients remained on the therapy, with one patient extending treatment beyond 16 months.
- The trial, enrolling 20 evaluable patients, met its primary endpoint of safety and tolerability.
- Full efficacy analyses, including progression-free survival and overall survival, are expected in coming months.
The big picture
Pancreatic cancer represents a significant unmet medical need with limited treatment options, particularly for patients who have progressed on first-line therapies. Can-Fite’s data, while preliminary, suggest namodenoson may offer a durable response in this challenging patient population. The extended treatment duration observed is a positive signal, but the ultimate success hinges on confirming efficacy in the planned full analysis and navigating a competitive landscape.
What we're watching
- Efficacy Confirmation
- The upcoming full efficacy analyses will be critical to determine if the observed disease stabilization translates into meaningful improvements in progression-free and overall survival, which are key value drivers.
- Regulatory Pathway
- Given the Orphan Drug Designation, the FDA's appetite for clinical data will be a key factor in determining the drug’s regulatory pathway, particularly if efficacy data are compelling.
- Competitive Landscape
- The success of namodenoson will be weighed against the existing and emerging therapies for pancreatic cancer, a field with significant unmet need and increasing competition.
Related topics